News AbbVie’s 8-week hepatitis C drug granted early access in UK AbbVie’s hepatitis C drug granted early access in UK
Views & Analysis The future of healthcare: the patient advocate and investor ... Examining the views of different stakeholders in the ecosystem supporting drug R&D.
Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News Skylark trials gene therapy for common form of child deafnes... Skylark Bio has dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
